Thanks to visit codestin.com
Credit goes to www.scribd.com

0% found this document useful (0 votes)
540 views4 pages

Perphenazine Drug Study

Perphenazine is an antipsychotic and antiemetic drug that blocks dopamine receptors in the brain. It is used to treat schizophrenia and control severe nausea and vomiting. Common side effects include dry mouth, blurred vision, dizziness, and drowsiness. Nurses monitor patients for cardiovascular issues and educate them about following their medication regimen and reporting any adverse reactions.

Uploaded by

shadow gonzalez
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
540 views4 pages

Perphenazine Drug Study

Perphenazine is an antipsychotic and antiemetic drug that blocks dopamine receptors in the brain. It is used to treat schizophrenia and control severe nausea and vomiting. Common side effects include dry mouth, blurred vision, dizziness, and drowsiness. Nurses monitor patients for cardiovascular issues and educate them about following their medication regimen and reporting any adverse reactions.

Uploaded by

shadow gonzalez
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd
You are on page 1/ 4

perphenazine

A Drug Study Presented to


Lendell Kelly B. Ytac, RN
Faculty, INAHS BSN-Program
Davao Oriental State University

_____________________________________________

In Partial Fulfillment
of the requirements for
NCM 117
Care of Clients with Maladaptive Patterns of Behavior
(Acute and Chronic)

By

Clint S. Ancog
Student Nurse, BSN-3A

March 18, 2022


Name of Drug Dosage/Frequency/ Mechanism of Indication Contraindication Side Effects/ Nursing
Time/ Route Action Adverse Effects Responsibilities
Generic Name: Route: P.O. Perphenazine blocks Perphenazine is -Coma SIDE EFFECTS:
perphenazine Onset: Variable postsynaptic indicated for ● dry mouth ● Monitor
Peak: 1-3 hours dopamine 2(D2) use in the -Concomitant ● pale skin cardiovascular
Brand Name: Duration: Unknown receptors in the treatment of large doses of ● stuffed nose status and
Fentazin, Trilafon mesolimbic and schizophrenia CNS depressants ● blurred vision vital signs
➣ Schizophrenia in medullary and for the ● widening or periodically.
Drug Classification: nonhospitalized chemoreceptor control of -Blood dyscrasias narrowing of the ●Explain
Antipyschotic, Patients trigger zone (CTZ), severe nausea pupils importance of
antiemetic thereby preventing and vomiting -Bone marrow ● dizziness combining
ADULTS AND the excess of in adults. depression drug therapy
Chemical make-up CHILDREN dopamine in the ADVERSE with
and effect: OLDER THAN brain. This leads to -Liver damage EFFECTS: psychotherapy.
Perphenazine is a AGE 12: reduction in ● Tell patient to
phenothiazine Initially, 4 to 8 mg psychotic symptoms, -Subcortical brain CNS: drowsiness, take exactly as
derivative in which the P.O. t.i.d. such as hallucinations damage. dizziness, insomnia, prescribed and
phenothiazine tricycle ➣ Schizophrenia in and delusions. vertigo, headache, to report
carries a chloro hospitalized hyperactivity, adverse
substituent at the 2- patients nocturnal confusion, reactions
position and a 3-[4-(2- ADULTS AND Pharmacokinetics: bizarre dreams, promptly.
hydroxyethyl)piperazin CHILDREN Absorption: Rate and tremor, ● Instruct
-1-yl]propyl group at OLDER THAN extent of absorption ataxia, slurring, patient to avoid
N-10. It has a role as a AGE 12: vary with exacerbation of sun exposure
phenothiazine Initially, 8 to 16 administration route. psychotic and to wear
antipsychotic drug, a mg P.O. two to four Oral tablet absorption symptoms, paranoid sunscreen
dopaminergic times daily, erratic and variable; reactions, outdoors to
antagonist and an increased p.r.n.; oral concentrate parkinsonism, prevent
antiemetic. It works by avoid dosages absorption much dystonias, akathisia, photosensitivity
decreasing abnormal greater than 64 mg more predictable. tardive dyskinesia, reaction.
excitement in the brain. daily. I.M. drug absorbed hyperreflexia, ● Advise patient
➣ Severe nausea rapidly. cerebrospinal fluid to consult
and vomiting Distribution: abnormality, prescriber
ADULTS: 8 to 16 Distributed widely catatonic-like state, before taking
mg P.O. daily in into body, including paradoxical other
divided breast milk. Drug is stimulation,seizures, prescription
doses, to a 91% to 99% protein- neuroleptic drugs
maximum of 24 mg. bound. After oral malignant syndrome or over-the-
tablet administration, CV: hypotension, counter
steady state serum orthostatic preparations.
levels achieved hypotension, ● Caution
within 4 to 7 days. hypertension, patient to avoid
Metabolism: peripheral edema, driving and
Metabolized ECG changes, other hazardous
extensively by liver; tachycardia, activities until
no active metabolites bradycardia, he knows how
formed. cardiac arrest, heart drug affects
Excretion: Mostly failure him.
excreted in urine via EENT: glaucoma, ● Instruct
kidneys; some in blurred vision, patient to avoid
feces via biliary tract. miosis, mydriasis, alcohol,
corneal and lens smoking,
deposits, caffeine, and
Pharmacodynamics: pigmentary herbs.
Thought to exert retinopathy,
antipsychotic effects oculogyric crisis,
by postsynaptic photophobia, nasal
blockade of CNS congestion,
dopamine receptors, dysphagia
thus inhibiting GI: nausea,
dopamine-mediated vomiting, diarrhea,
effects; antiemetic constipation,
effects are attributed obstipation,
to dopamine receptor abnormal tongue
blockade in the color or movement,
medullary dry mouth,
chemoreceptor anorexia, adynamic
trigger zone. Has
References:

Schull, P. (2013). McGraw-Hill Nurse’s Drug Handbook Seventh Edition. McGraw-Hill Companies, Inc.

Skidmore-Roth, L. (2021). Mosby’s 2021 Nursing Drug Reference, 3251 Riverport Lane St. Louis, Missouri 63043

Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. Drugbank: a comprehensive resource for
in silico drug discovery and exploration. Nucleic Acids Res. 2006 Jan 1;34 (Database issue):D668-72. 16381955.

You might also like